Treatment with IL5-/IL-5 receptor antagonists in drug reaction with eosinophilia and systemic symptoms (DRESS) (2024)

Journal List
Springer Nature - PMC COVID-19 Collection
PMC9396594

As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsem*nt of, or agreement with, the contents by NLM or the National Institutes of Health.
Learn more: PMC Disclaimer | PMC Copyright Notice

Allergo J Int. 2022 Aug 23 : 1–8.

doi:10.1007/s40629-022-00224-7 [Epub ahead of print]

PMCID: PMC9396594

PMID: 36035809

Anna Gschwend, PhD,¹ Arthur Helbling, MD,¹ Laurence Feldmeyer, PhD,² Ulrich Mani-Weber, MD,³ Cordula Meincke, MD,¹ Kristine Heidemeyer, MD,² Simon Bossart, MD,² and Lukas Jörg, MD¹

Author information Article notes Copyright and License information PMC Disclaimer

Abstract

Purpose

Drug reaction with eosinophilia and systemic symptoms (DRESS) is asevere delayed drug hypersensitivity reaction with exanthema, eosinophilia, and organ manifestations. After culprit drug withdrawal, systemic corticosteroids (CS) are the most widely used treatment, often requiring high doses for months. Blocking the IL-5/IL‑5 receptor axis with mepolizumab, reslizumab, and benralizumab is apromising targeted treatment with agood safety profile and no immunosuppressive effect. The aim of this study is to summarize current experience with the anti-IL5/IL-5-receptor therapy in DRESS.

Methods

Aretrospective analysis of all patients diagnosed with DRESS and treated with mepolizumab, reslizumab, or benralizumab in DRESS was performed. In addition, aPubMed–Medline search for publications on DRESS with anti-IL-5/IL‑5 receptor treatment was performed.

Results

Of the 14cases identified, 6patients were treated with mepolizumab, 6with benralizumab, 1patient with reslizumab, and 1patient was switched from benralizumab to mepolizumab. The main indication for an IL‑5 blockade was atherapy-refractory course (7/14 [50.0%]), recurrent relapses (3/14 [21.4%]), and severe organ dysfunction (2/14 [14.3%]). In 13/14 (93%) cases, arapid clinical improvement with suppression of eosinophilia and reduction of CS could be achieved. In all but two cases under mepolizumab (dose 100–600 mg) or reslizumab (dose according to body weight), two or more doses were necessary until resolution of DRESS. In 4/7cases under benralizumab, asingle 30 mg dose was sufficient.

Conclusion

Blockade of the IL-5/IL‑5 receptor axis appears to be apromising treatment in DRESS with fast clinical improvement, which may allow more rapid reduction of CS, and agood safety profile. In addition, asummary of recommendations on when to use blockade of the IL-5/IL‑5 receptor axis in DRESS treatment is provided.

Keywords: Eosinophilia, Benralizumab, Mepolizumab, Reslizumab, Drug hypersensitivity

Introduction

Drug reaction with eosinophilia and systemic symptoms (DRESS) is arare but severe, delayed drug hypersensitivity reaction (DHR) [1]. DRESS can mimic infections, hematologic malignancy, and autoimmune diseases with the main feature of (often) severe eosinophilia [2]. Organ manifestations involving kidneys, gastrointestinal tract, lungs, heart, and liver are typical, with the liver being the most commonly affected organ [3]. The course of DRESS is frequently characterized by viral reactivations such as human herpesvirus6 (HHV6), HHV7, Epstein-Barr virus (EBV), and cytomegalovirus (CMV) [3, 4]. Recurrent spontaneous relapses occurring for months, triggered by viral reactivation, reduction of systemic corticosteroids (CS) or immunosuppressive drugs, or introduction of new drugs, are typical in the DRESS disease course [5]. Complications of DRESS—even after years—include the development of autoimmune diseases, multiple drug hypersensitivity, or persistent organ damage [5, 6]. Even under careful treatment, mortality from DRESS ranges from 2to 10% [3].

Methods

Aretrospective analysis of all patients diagnosed with DRESS and treated with mepolizumab, reslizumab, or benralizumab in DRESS was performed. Cases were obtained from adrug allergy database of the Division of Allergy and Clinical Immunology, Inselspital Bern. The study was approved by the local ethics committee (Kantonale Ethikkommission Universität Bern ID 2018-02192), all patients signed the informed consent. Medical records of each patient were reviewed for clinical features such as exanthema, fever, eosinophilia, presence of atypical lymphocytes, organ involvement, involved drugs, dose and duration of IL-5/IL-5R blockade, and outcome. We calculated the Regiscar score for each case based on clinical features, which classifies aDRESS as definitive case (≥ 6points), probable case (4–5points), possible case (2–3points), or no case (< 2points) [3]. To supplement our data with published cases, we searched PubMed–Medline for publications on DRESS with IL-5/IL-5R treatment with the following terms: drug reaction with eosinophilia and systemic symptoms, DRESS, severe drug hypersensitivity, drug-induced hypersensitivity syndrome or DIHS and IL‑5 blockade, IL‑5 treatment, benralizumab, mepolizumab, reslizumab. The literature was evaluated for clinical features of DRESS, indication for IL‑5 blockade, dose and duration of IL-5/IL-5R blockade, and outcome. Study analysis was performed using Graphpad Prism8 (GraphPad Software, Inc, La Jolla, CA, USA). All results are summarized with descriptive statistics. Proportions are expressed as percentages.

Results

In our database, we identified 4patients with aDRESS diagnosis, based on clinical signs with aRegiscar score of > 4points and treated with anti-IL5/IL-5R antibodies [3]. Three individuals were included in our study, one refused to participate (Table1). The PubMed–Medline search revealed 11cases published with DRESS and treated with anti-IL5 drugs (Table2; [22–29]). Of the 14cases, 6were treated with mepolizumab, 6with benralizumab, 1with reslizumab, and 1was switched from benralizumab to mepolizumab during the DRESS disease course. The median age was 58years (interquartile range [IQR] 49.5–68.5), the proportion of females was 8/14 (57.1%). Indication for an IL‑5 blockade was atherapy-refractory course under CS with persisting or increasing eosinophilia (6/14 [42.9%], cases1, 4–5, 7–9), severe organ dysfunction (3/14 [21.4%], cases 3, 6, 12), recurrent relapses (3/14 [21.4%], cases1, 11, 13), continued treatment with the causing drug (1/14 [7.1%], case 14), and concomitant septic shock (1/14 [7.1%], case2). The median Regiscar score was 6[3]. All patients were initially treated with high dose systemic steroids (> 50 mg prednisone equivalent per day); two with additional immunosuppressive drugs (cases 10and 11), three with intravenous immunoglobulins (cases2, 6, and 13).

Table 1

Patient characteristics of three cases with drug reaction with eosinophilia and systemic symptoms (DRESS) from the Inselspital Bern database

	Patient1	Patient2	Patient3
Demographics
Age	62	70	39
Gender	m	m	m
Culprit drug	Amoxicillin	Piperacillin Vancomycin Meropenem	Metamizol suspected
Organ involvement
Regiscar score	7	6	6
Eosinophilia (max.)	4.75 G/l	4.16 G/l	1.28 G/l
Lymphadenopathy	Yes	No	Yes
Fever	Yes	Yes	Yes
Exanthema	Yes	Yes	Yes
Features of exanthema	Generalized MPE Skin desquamation	Generalized erythema with pinpoint pustules Skin blisters and erosion	Generalized MPE Skin desquamation
Liver	Yes	No	Yes
Kidney	Yes	Yes	No
Lung	No	No	No
Heart	No	No	Yes
Viral reactivation	No	n/a	No
Basic treatment	Methylprednisolone/Prednisolone	Solucortef Prednisolone IVIG	Prednisolone
IL-5/IL-5R antagonist used	Mepolizumab	Mepolizumab	Benralizumab
Indication	Therapy refractory under systemic steroids	Severe sepsis under systemic steroids	Persisting hepatitis under systemic steroids
Number of doses	3	1	3
Outcome	Rapid improvement, systemic steroid tapering possible	Minor improvement	Improvement of hepatitis, steroid tapering possible

Open in a separate window

IVIGintravenous immunoglobulin, MPEMaculopapular exanthema, Mmale, n/anot applicable, G/LGiga per litre

Table 2

Published cases on drug reaction with eosinophilia and systemic symptoms (DRESS) and IL-5/IL-5R blockade

Case	Gender	Age	Reaction	Regiscar	Trigger	Max. Eos G/l	IL‑5 blocker	Dose (mg)	Doses, N	Reported outcome of DRESS	Base treatment	Ref
4	f	54	DRESS	7	Esomeprazole and piperacillin suspected	> 4	Benralizumab	30	1	Clinical improvement	Methylprednisolone	22
5	f	58	DRESS	8	Midazolam suspected	> 4	Benralizumab	30	1	Clinical improvement, lethal outcome (COVID-19)	Methylprednisolone	22
6	m	43	DRESS	8	Cefepime suspected	6.7	Benralizumab	30	2	Clinical improvement	Methylprednisolone IVIG	23
7	f	87	DRESS	5	Allopurinol and pregabalin suspected	1.25	Benralizumab	30	1	Clinical improvement	Methylprednisolone	24
8	m	74	DRESS	6	Allopurinol suspected	5.31	Benralizumab	30	1	Clinical improvement	Methylprednisolone	24
9	f	67	DRESS	7	Ibuprofen and paracetamol suspected	19.35	Benralizumab Mepolizumab	30/100 mg	1/2	Clinical improvement, relapse	Methylprednisolone	24
10	f	45	DRESS	n/a	Lamotrigine suspected	n/a	Mepolizumab	300–500 mg	> 4	Clinical improvement	Methylprednisolone Mycophenolate mofetil Cyclosporine	25
11	f	50	DRESS/AGEP overlap	n/a	Ciprofloxacin suspected	1.5	Mepolizumab	300 mg	2	Clinical improvement	Prednisolone Methylprednisolone Cyclophosphamide Cyclosporine	26
12	m	56	DRESS	> 4	Pregabalin suspected	7.1	Mepolizumab	2 × 300mg 1day apart, then 300/100 mg	> 3	Clinical improvement	Methylpredisolone	27
13	f	56	DRESS	6	Sulfamethoxazole/trimethoprim suspected	6.4	Mepolizumab	100 mg	3	Clinical improvement, relapse	Dexamethasone IVIG	28
14	f	62	DRESS	5	Imatinib (not stopped)	1.69	Reslizumab	100–200 mg	2	Clinical improvement, re-exposure with imatinib, relapse	Dexamethasone	29

Open in a separate window

IVIGintravenous immunoglobulin, Ffemale, Mmale, n/anot applicable

Mepolizumab in DRESS

Out of 14patients (50%) were treated with mepolizumab, including the subject treated with both benralizumab and mepolizumab (cases1, 2, 9–13) [24–28]. Two of them from our clinic (Table1): Amoxicillin was identified as the causal drug for DRESS in a62-year-old man (case1). Sensitization to amoxicillin was documented later by alymphocyte transformation test (LTT). Since treatment with systemic high-dose CS did not result in any clinical improvement (hepatitis, renal failure under dialysis), 100 mg mepolizumab was given at day14. Within 2days, clinical improvement was noticed with normalization of blood eosinophilia (0.04 G/l). Due to relapses (exanthema, facial swelling, increases of transaminases (2-fold) and increasing eosinophilia (0.44 G/l and 0.75 G/l, respectively)), two additional injections of 100 mg mepolizumab were given at day 37and 117, resulting in complete remission of DRESS. The other patient, a 70-year-old man, received asingle dose of 100 mg mepolizumab because of atoxic epidermal necrolysis (TEN)/acute generalized exanthematous pustulosis (AGE)P/DRESS overlap syndrome (case2). While peripheral eosinophils declined rapidly, clinical condition improved slowly. As mepolizumab did not have asignificant impact on the clinical course, possibly because TEN was the primary pathophysiological mechanism of the reaction, it was stopped.

Mepolizumab had agood therapeutic effect, but similar as in our first patient, it had to be administered more than once in all cases published. In the first article on mepolizumab used in DRESS, initial improvement was achieved with high-dose CS [28]. Clinical course, however, was characterized by multiple severe relapses, even under treatment with CS. Asingle injection of 100 mg mepolizumab then resulted in normalization of the eosinophils within 3days and improvement of the skin rash within aweek. Nevertheless because of relapses, continuation of CS for 3months was necessary. In two other reports, relapses were successfully treated with mepolizumab: necrotizing eosinophilic myocarditis was initially treated with 300 and 500 mg mepolizumab [25]. Symptoms were in control despite CS reduction, but treatment had to be continued for almost 1year. Truong etal. also reported asuccessful outcome of eosinophilic myocarditis which was treated with 300 mg mepolizumab twice with a4-week interval in combination with cyclophosphamide and cyclosporine [26]. Another report of asevere DRESS with pulmonary involvement showed asignificant improvement within 13days after administration of 600 mg mepolizumab (two 300 mg doses over 2consecutive days) [27]. Nonetheless, alonger treatment period with mepolizumab at 4‑week intervals was required. The 7thcase is described in the section “Benralizumab” [24].

Benralizumab in DRESS

To date seven DRESS case reports with patients treated with benralizumab have been published, including the one from our database (Table1; [22–24]): The suspected trigger in our case was metamizole (case3). Although CS were introduced, the patient developed persistent, histologically proven eosinophilic hepatitis. Benralizumab was given three times at adose of 30 mg at monthly intervals. This procedure led to arapid suppression of eosinophils and the hepatitis improved. CS could be reduced to under 10 mg prednisolone after 7months with only mild transient elevation of liver transaminases.

Remarkably, in most of the reported cases (4/7) asingle dose of benralizumab 30 mg seems to be sufficient for recovery [22, 24]. Schmid-Grendelmeier etal. reported on 2patients with DRESS and concomitant severe coronavirus disease 2019 (COVID-19) infection requiring intensive care treatment [22]. In both cases, rapid decrease of peripheral eosinophils within 2days was noticed together with clinical improvement of skin and liver inflammation. One subject died because of COVID-19 complications. The same group published 3additional case reports on DRESS [24]. Two of them revealed arapid and sustained improvement after asingle dose of 30 mg benralizumab. The third subject had arelapse 4months later but improved after afurther anti-IL5treatment with mepolizumab (switched because of lack of benralizumab).

Dose-repetition of benralizumab was also necessary in the publication by Mesli etal. to safely taper CS [23]. Severe hemophagocytic lymphohistiocytosis with increasing eosinophilia despite CS led to the administration of 30 mg benralizumab, resulting in rapid improvement of lymphohistiocytosis, but also rash and other organ manifestations within 16days. To be able to reduce the systemic steroids, another injection was necessary after 4weeks.

Reslizumab in DRESS

In the current literature, only one case has been published [29]. Interestingly, the authors described that the suspected causing drug, imatinib, could be reintroduced under the treatment of IL‑5 blockade. Whether or not imatinib was the culprit drug remains unclear since it was not tested according to the recommendations for drug allergy. Re-exposures with imatinib led twice to DRESS relapses. The administration of reslizumab at doses of 100 mg resulted in arapid normalization of peripheral eosinophilia and improvement of clinical symptoms. After 2weeks, because of amild rash, reslizumab at adose of 200 mg was administered, followed by complete recovery. Subsequently the patient tolerated imatinib for at least 2more years.

Discussion

Although IL‑5 axis targeted treatments are used nowadays in numerous TH-2-mediated diseases, there are few reports concerning their use in eosinophilic complications such as drug hypersensitivity reactions. To date, 11case reports have been published, with 3more cases from our database [22–29]. Currently, IL-5/IL-5R blockade is mainly used in refractory DRESS, in severe DRESS relapses, and in cases with severe organ manifestation. In the majority of cases (13/14, 93%), rapid improvement with good suppression of peripheral eosinophilia and consecutive reduction of CS could be achieved. Schmid-Grendelmeier etal. showed that treatment with benralizumab not only decreased IL‑4 and IL‑5 levels, but also had an influence on proteins, related to cytotoxic T‑cell function [22]. Several months of treatment are probably necessary, especially when IL‑5 antagonists such as mepolizumab and reslizumab are used. In two cases of our database as well as in published cases, relapses could be documented afew weeks after mepolizumab administration [27, 28].

In brief, 2–3 injections of mepolizumab or reslizumab at monthly intervals are necessary for complete remission even at doses up to 600 mg. On the contrary benralizumab once at adose of 30 mg was sufficient in most patients. Due to the mode of action with depletion of eosinophils, it is expected that fewer injections are necessary with benralizumab. Although it seems that benralizumab has amore pronounced effect on DRESS, the choice of which drug to use is probably based on availability, as it is an off-label treatment. The small number of cases does not allow areliable statement which of the three drugs is comparatively more effective.

An interesting observation is the one case with DRESS who tolerated imatinib, the putative DRESS-causing drug, for at least 2years after treatment with reslizumab, even after discontinuation of IL‑5 blockade [29]. Unfortunately, no workup was performed to confirm imatinib as the causative drug.

The selection of patients to treat with IL-5/IL-5R blockade is of great importance. In our collective, the patient with the overlap of TEN, AGEP, and DRESS showed little clinical improvement, which may indicate that the underlying DHR of TEN/AGEP was probably stronger than that of DRESS, and IL‑5 was not the primary cytokine involved (case2).

Our analysis of 14DRESS cases suggests that by blocking the IL-5/IL-5R pathway, rapid improvement can be achieved in most severe DRESS cases. Within 2days to 2weeks, arapid decrease in peripheral eosinophils is observed, accompanied by clinical improvement in most patients. The therapeutic effects of CS or immunosuppressants, which are usually administered before or concomitantly with the administration of an IL-5-blocking drug, must be considered when evaluating therapeutic success in the clinical course. The potential benefit of IL-5/IL-5R blockade is the targeted reduction in dose or duration of CS treatment, thereby minimizing CS-induced complications and disease burden. Furthermore, IL-5/IL-5R blockade seems to be effective not only in the initial DRESS course, but also in DRESS relapses. Disadvantages of IL-5/IL-5R blockade are the high cost of treatment, regardless of the biologic used, and potential side effects such as headache, nasopharyngitis, and respiratory tract infections. On the other hand, using it for afew months can shorten hospitalization and avoid DRESS-associated complications, which in turn can prevent subsequent costs.

Despite clinical improvement in most severe DRESS cases, some questions remain unanswered because of the small number of DRESS reports with treatment of IL‑5 blocking drugs. Whether early blockade of the IL‑5 axis can truly prevent or at least reduce late complications such as immune dysregulation, multiple drug hypersensitivity syndrome, or persistent organ damage cannot yet be answered. It is also uncertain whether IL-5/IL5R blockade is useful in preventing severe DRESS or could be used directly—in addition to CS—for moderate or mild forms of DRESS. Currently, treatment with mepolizumab, benralizumab, and reslizumab will mostly remain apotential treatment for severe DRESS courses [30]. Based on the reported cases, we propose ause of an IL5/IL-5R blockade in the following situations (Table3):

Early use in severe DRESS courses with need of intensive care medicine treatment
Lack of clinical improvement under high dose of CS (≥ 1 mg/kg prednisone equivalent per day, treatment for > 1week) and persistent eosinophilia ≥ 1.0 G/l
Additional use of an immunosuppressive drug needed despite high dose of CS
Severe DRESS with concomitant infectious disease
Evidence of severe/life threatening organ damage (e.g., myocarditis, eosinophilic pneumonia, hepatitis) at the beginning or DRESS relapse

Table 3

Recommendation for the use of IL-5/IL-5R antagonists in drug reaction with eosinophilia and systemic symptoms

When to use IL-5/IL-5R blockade?

–Severe DRESS course with need of intensive care medicine

–No clinical improvement under high-dose systemic steroids (≥ 1 mg/kg prednisone equivalent per day) for ≥ 7days and persistent eosinophilia above 1.0 G/l

–Additional use of an immunosuppressive drug (e.g., cyclosporine) needed despite high-dose CS

–Severe DRESS with concomitant infectious disease

–Evidence of severe/life threatening organ damage (e.g., myocarditis, eosinophilic pneumonia, hepatitis) at the beginning or at aDRESS relapse

Duration of treatment

–Recommendation of 3months at 4‑week intervals for mepolizumab and reslizumab

–Asingle dose of benralizumab might be sufficient

Treatment dose recommendation

–Mepolizumab: 300 mg

–Benralizumab: 30 mg

–Reslizumab: according to body weight

Open in a separate window

For treatment duration, we recommend aperiod of at least 3months, especially if mepolizumab or reslizumab is used with injections at 4‑week intervals at adose of 300 mg or according to the body weight. For benralizumab, asingle dose at 30 mg might be sufficient.

The limitation of our study is the small case number and the lack of comparability in acontrol group. Therefore, prospective studies on the treatment of DRESS are urgently needed.

Conclusion

Patients with DRESS often require longer-term immunosuppressive treatment, especially with high dose CS. Blockade of the IL-5/IL-5R axis appears to be apromising treatment, at least in severe DRESS, which may allow more rapid reduction of CS and shortening of hospital stay. Nevertheless, it is usually necessary to monitor the therapy and clinical course over several months.

Acknowledgements

The authors thank Lester Thoo and Werner Pichler for critically editing the manuscript.

Funding

There was no funding for this study.

Author Contribution

Lukas Jörg and Anna Gschwend contributed to the study conception, design and data collection. Data analysis and interpretation was performed by all authors. The manuscript was written by Lukas Jörg and Anna Gschwend. All authors critically reviewed the manuscript and approved the final version.

Funding

Open access funding provided by University of Bern

Declarations

Conflict of interest

L.Jörg has received advisory board fees from Astra Zeneca and speaker fees from GSK. A.Helbling has received advisory board fees from Astra Zeneca and GSK. A.Gschwend has received speaker fees from GSK. L.Feldmeyer, U.Mani-Weber, C.Meincke, K.Heidemeyer and S.Bossart declare that they have no competing interests.

Ethical standards

The study was approved by the local ethics committee (Kantonale Ethikkommission Bern ID 2018-02192). Consent to participate: All patients included gave informed consent for study participation and data publication. Confirmation of unpublished work: All authors approved the content of the manuscript and this submission. All authors listed have contributed sufficiently to the project to be included as authors.

Footnotes

Anna Gschwend and Lukas Jörg contributed equally to this article and should be considered joint first and last authors.

References

1. Shiohara T, Mizukawa Y. Drug-induced hypersensitivity syndrome (DiHS)/drug reaction with eosinophilia and systemic symptoms (DRESS): an update in 2019. Allergol Int. 2019;68(3):301–308. doi:10.1016/j.alit.2019.03.006. [PubMed] [CrossRef] [Google Scholar]

2. Lee HY, Walsh S, Creamer D. Initial presentation of DRESS: often misdiagnosed as infections. Arch Dermatol. 2012;148(9):1085–1087. doi:10.1001/archdermatol.2012.1079. [PubMed] [CrossRef] [Google Scholar]

3. RegiSCAR study group. Kardaun SH, Sekula P, Valeyrie-Allanore L, Liss Y, Chu CY, Creamer D, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol. 2013;169(5):1071–1080. doi:10.1111/bjd.12501. [PubMed] [CrossRef] [Google Scholar]

4. Shiohara T, Inaoka M, Kano Y. Drug-induced hypersensitivity syndrome (DIHS): areaction induced by acomplex interplay among herpesviruses and antiviral and antidrug immune responses. Allergol Int. 2006;55(1):1–8. doi:10.2332/allergolint.55.1. [PubMed] [CrossRef] [Google Scholar]

5. Jörg L, Helbling A, Yerly D, Pichler WJ. Drug-related relapses in drug reaction with eosinophilia and systemic symptoms (DRESS) Clin Transl Allergy. 2020;10(1):52. doi:10.1186/s13601-020-00359-2. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

6. Ushigome Y, Kano Y, Ishida T, Hirahara K, Shiohara T. Short- and long-term outcomes of 34patients with drug-induced hypersensitivity syndrome in asingle institution. J Am Acad Dermatol. 2013;68(5):721–728. doi:10.1016/j.jaad.2012.10.017. [PubMed] [CrossRef] [Google Scholar]

7. Shiohara T, Kano Y. Drug reaction with eosinophilia and systemic symptoms (DRESS): incidence, pathogenesis and management. Expert Opin Drug Saf. 2017;16(2):139–147. doi:10.1080/14740338.2017.1270940. [PubMed] [CrossRef] [Google Scholar]

8. Nguyen E, Yanes D, Imadojemu S, Kroshinsky D. Evaluation of cyclosporine for the treatment of DRESS syndrome. JAMA Dermatol. 2020;156(6):704–706. doi:10.1001/jamadermatol.2020.0048. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

9. Esposito AJ, Murphy RC, Toukatly MN, Amro OW, Kestenbaum BR, Najafian B. Acute kidney injury in allopurinol-induced DRESS syndrome: acase report of concurrent tubulointerstitial nephritis and kidney-limited necrotizing vasculitis. Clin Nephrol. 2017;87(6):316–319. doi:10.5414/CN108966. [PubMed] [CrossRef] [Google Scholar]

10. Kim D, Kobayashi T, Voisin B, Jo JH, Sakamoto K, Jin SP, et al. Targeted therapy guided by single-cell transcriptomic analysis in drug-induced hypersensitivity syndrome: acase report. Nat Med. 2020;26(2):236–243. doi:10.1038/s41591-019-0733-7. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

11. Choquet-Kastylevsky G, Intrator L, Chenal C, Bocquet H, Revuz J, Roujeau JC. Increased levels of interleukin 5 are associated with the generation of eosinophilia in drug-induced hypersensitivity syndrome. Br J Dermatol. 1998;139(6):1026–1032. doi:10.1046/j.1365-2133.1998.02559.x. [PubMed] [CrossRef] [Google Scholar]

12. Xu J, Jiang F, Nayeri F, Zetterström O. Apoptotic eosinophils in sputum from asthmatic patients correlate negatively with levels of IL-5 and eotaxin. Respir Med. 2007;101(7):1447–1454. doi:10.1016/j.rmed.2007.01.026. [PubMed] [CrossRef] [Google Scholar]

13. Brusselle GG, Koppelman GH. Biologic therapies for severe asthma. N Engl J Med. 2022;386(2):157–171. doi:10.1056/NEJMra2032506. [PubMed] [CrossRef] [Google Scholar]

14. EGPA Mepolizumab Study Team. Wechsler ME, Akuthota P, Jayne D, Khoury P, Klion A, Langford CA, et al. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med. 2017;376(20):1921–1932. doi:10.1056/NEJMoa1702079. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

15. Gevaert P, Han JK, Smith SG, Sousa AR, Howarth PH, Yancey WS, et al. The roles of eosinophils and interleukin-5 in the pathophysiology of chronic rhinosinusitis with nasal polyps. Int Forum Allergy Rhinol. 2022 doi:10.1002/alr.22994. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

16. HES Mepolizumab study group. Roufosse F, Kahn JE, Rothenberg ME, Wardlaw AJ, Klion AD, Kirby SY, et al. Efficacy and safety of mepolizumab in hypereosinophilic syndrome: a phase III, randomized, placebo-controlled trial. J Allergy Clin Immunol. 2020;146(6):1397–1405. doi:10.1016/j.jaci.2020.08.037. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

17. Straumann A, Conus S, Grzonka P, Kita H, Kephart G, Bussmann C, et al. Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: arandomised, placebo-controlled, double-blind trial. Gut. 2010;59(1):21–30. doi:10.1136/gut.2009.178558. [PubMed] [CrossRef] [Google Scholar]

18. Spergel JM, Rothenberg ME, Collins MH, Furuta GT, Markowitz JE, Fuchs G, et al. Reslizumab in children and adolescents with eosinophilic esophagitis: results of adouble-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol. 2012;129(2):456–463.e1–3. doi:10.1016/j.jaci.2011.11.044. [PubMed] [CrossRef] [Google Scholar]

19. Khatri S, Moore W, Gibson PG, Leigh R, Bourdin A, Maspero J, et al. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. J Allergy Clin Immunol. 2019;143(5):1742–1751.e7. doi:10.1016/j.jaci.2018.09.033. [PubMed] [CrossRef] [Google Scholar]

20. Bourdin A, Shaw D, Menzies-Gow A, FitzGerald JM, Bleecker ER, Busse WW, et al. Two-year integrated steroid-sparing analysis and safety of benralizumab for severe asthma. J Asthma. 2021;58(4):514–522. doi:10.1080/02770903.2019.1705333. [PubMed] [CrossRef] [Google Scholar]

21. Virchow JC, Katial R, Brusselle GG, Shalit Y, Garin M, McDonald M, Castro M. Safety of reslizumab in uncontrolled asthma with eosinophilia: a pooled analysis from 6 trials. J Allergy Clin Immunol Pract. 2020;8(2):540–548.e1. doi:10.1016/j.jaip.2019.07.038. [PubMed] [CrossRef] [Google Scholar]

22. Schmid-Grendelmeier P, Steiger P, Naegeli MC, Kolm I, Valérie CCL, Maverakis E, Brüggen MC. Benralizumab for severe DRESS in two COVID-19patients. J Allergy Clin Immunol Pract. 2021;9(1):481–483.e2. doi:10.1016/j.jaip.2020.09.039. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

23. Mesli F, Dumont M, Soria A, Groh M, Turpin M, Voiriot G, et al. Benralizumab: a potential tailored treatment for life-threatening DRESS in the COVID-19 era. J Allergy Clin Immunol Pract. 2021;9(9):3529–3531.e1. doi:10.1016/j.jaip.2021.06.047. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

24. Lang CCV, Schmid-Grendelmeier P, Maverakis E, Brüggen MC. Reply to “Benralizumab: a potential tailored treatment for life-threatening DRESS in the COVID-19 era” J Allergy Clin Immunol Pract. 2021;9(9):3531–3532. doi:10.1016/j.jaip.2021.06.048. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

25. Kowtoniuk R, Pinninti M, Tyler W, Doddamani S. DRESS syndrome-associated acute necrotizing eosinophilic myocarditis with giant cells. BMJ Case Rep. 2018 doi:10.1136/bcr-2018-226461. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

26. Truong K, Kelly S, Bayly A, Smith A. Successful mepolizumab treatment for DRESS-induced refractory eosinophilic myocarditis and concurrent thyroiditis. BMJ Case Rep. 2021;14(7):e242240. doi:10.1136/bcr-2021-242240. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

27. Thein OS, Sutton B, Thickett DR, Parekh D. Mepolizumab rescue therapy for acute pneumonitis secondary to DRESS. BMJ Case Rep. 2019;12(10):e231355. doi:10.1136/bcr-2019-231355. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

28. Ange N, Alley S, Fernando SL, Coyle L, Yun J. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome successfully treated with mepolizumab. J Allergy Clin Immunol Pract. 2018;6(3):1059–1060. doi:10.1016/j.jaip.2017.10.020. [PubMed] [CrossRef] [Google Scholar]

29. Park H, Choi GS, Lee EM. Successful treatment of Imatinib-induced DRESS syndrome using reslizumab without cessation of Imatinib: a case report. Case Rep Oncol. 2021;14(3):1548–1554. doi:10.1159/000519471. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

30. Maverakis E, Ji-Xu A, Brüggen M-C. Targeting interleukin-5 with benralizumab: anovel treatment for drug rash with eosinophilia and systemic symptoms (DRESS) Allergy. 2022 doi:10.1111/all.15283. [PubMed] [CrossRef] [Google Scholar]

Articles from Allergo Journal International are provided here courtesy of Nature Publishing Group